Market Research Logo

Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Table of Contents
List of Tables
List of Figures
Kolltan Pharmaceuticals, Inc. Snapshot
Kolltan Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Kolltan Pharmaceuticals, Inc. - Research and Development Overview
Key Therapeutic Areas
Kolltan Pharmaceuticals, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Kolltan Pharmaceuticals, Inc. - Pipeline Products Glance
Kolltan Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Kolltan Pharmaceuticals, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Kolltan Pharmaceuticals, Inc. - Drug Profiles
KTN-0158
Product Description
Mechanism of Action
R&D Progress
KTN-3379
Product Description
Mechanism of Action
R&D Progress
KIT-SG3227
Product Description
Mechanism of Action
R&D Progress
KTN-0182A
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugate to Antagonize ALK Receptor for Oncology
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugate to Inhibit Axl for Cancer, Inflammation and Infection
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugate to Target ErbB-3 for Oncology
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit c-MET for Cancer
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit FGFR4 for Cancer
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit RON for Cancer
Product Description
Mechanism of Action
R&D Progress
Kolltan Pharmaceuticals, Inc. - Pipeline Analysis
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Target
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates
Kolltan Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Kolltan Pharmaceuticals, Inc., Key Information
Kolltan Pharmaceuticals, Inc., Key Facts
Kolltan Pharmaceuticals, Inc. - Pipeline by Indication, 2016
Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Kolltan Pharmaceuticals, Inc. - Phase I, 2016
Kolltan Pharmaceuticals, Inc. - Preclinical, 2016
Kolltan Pharmaceuticals, Inc. - Discovery, 2016
Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016
Kolltan Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
Kolltan Pharmaceuticals, Inc., Subsidiaries
List of Figures
Kolltan Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016
Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016

Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Kolltan Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kolltan Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Kolltan Pharmaceuticals, Inc.
The report provides overview of Kolltan Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report assesses Kolltan Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report features Kolltan Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Kolltan Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Kolltan Pharmaceuticals, Inc.
Identify potential new clients or partners in the target demographic
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Kolltan Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;